Table 1.
Summary of patient baseline characteristics
| characteristics | Patients in group A | Patients in group B | p value |
|---|---|---|---|
| Age (Year) | 68.50 ± 17.07 | 52.75 ± 14.08 | 0.205 |
| Sex (Male/Female) | 3 (75%)/1(25%) | 1(25%)/3(75%) | 0.157 |
| HBV infection (No/Yes) | 3 (75%)/1(25%) | 3 (75%)/1(25%) | 1.000 |
| Child-Pugh class (A/B) | 2 (50%)/2 (50%) | 0 (0%)/4 (100%) | 0.102 |
| CEA (ng/mL) | 3.47 ± 1.73 | 2.41 ± 1.20 | 0.356 |
| CA19-9 (U/mL) | 358.13 ± 290.97 | 731.25 ± 379.37 | 0.060 |
| Total bilirubin (μmol/L) | 73.18 ± 31.48 | 106.36 ± 18.68 | 0.131 |
| ECOG performance status (0/1) | 3 (75%)/1 (25%) | 2 (50%)/2 (50%) | 0.465 |
| Extent of disease (N0M0/N1M0/N2M0) | 4 (100%)/0 (0%)/0 (0%) | 2 (50%)/1 (25%)/1 (25%) | 0.264 |
| Treatment responsea (CR/PR/SD/PD) | 0 (0%)/3 (75%)/1 (25%)/0 (0%) | 0 (0%)/0 (0%)/0 (0%)/4 (100%) | 0.018 |
| mOS (months) | 25.00（15.66–34.34） | 3.00（0.06–5.94） | 0.007 |
| mPFS (months) | 12.00（3.18–20.82） | 1.90（1.51–2.29） | 0.007 |
HBV: hepatitis B virus; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; ECOG: Eastern Cooperative Oncology Group; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; mOS: median overall survival; mPFS: median progression-free survival.
a
Treatment response was assessed according to the Response Evaluation Criteria in Solid Tumors guidelines (version 1.1).